Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
11 mai 2022 07h00 HE
|
Cognition Therapeutics, Inc.
Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators ...
CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
04 mai 2022 17h54 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of...
Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
04 mai 2022 16h01 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases...
Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD
03 mai 2022 08h00 HE
|
Cognition Therapeutics, Inc.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the...
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
25 avr. 2022 16h01 HE
|
Cognition Therapeutics, Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
25 avr. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference
06 avr. 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
30 mars 2022 07h00 HE
|
Cognition Therapeutics, Inc.
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program -- Conference call and...
Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results
22 mars 2022 08h00 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022
10 mars 2022 07h30 HE
|
Cognition Therapeutics, Inc.
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...